Formulation Development
INmune Bio Provides Update on Two Patients From Phase 1b Alzheimer’s Disease Trial Who Continue to Receive XPro Under Compassionate Use for Over 3 Years
INmune Bio Inc. recently shared an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro for…
Editas Medicine & Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Editas Medicine, Inc. recently announced a 2-year extension to the collaboration with Bristol Myers Squibb under which the parties may research, develop, and commercialize autologous…
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics Inc. recently announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen…
Creyon Bio & Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines for Neurodegenerative Diseases
Creyon Bio, Inc. and Cajal Neuroscience recently announced a partnership to develop novel OBMs for neurodegenerative diseases. Under the collaboration, the companies are developing antisense…
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Aileron Therapeutics, Inc. recently announced positive data from Cohort 1 of the ongoing Phase 1b clinical trial evaluating the safety and tolerability of inhaled LTI-03…
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles With siRNA Targeting p65 Protein in Treatment of Cancer & Inflammation
Altamira Therapeutics Ltd. recently announced it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the….
Adare Expands Global High Potency Handling & Packaging Capabilities
Adare Pharma Solutions, a global technology-driven CDMO specializing in oral dosage forms, recently announced expansions of its high potency handling capabilities in the….
SPECIAL FEATURE - Prefilled Syringes & Parenteral Delivery: Next-Gen Injections Feature Technology & Reconstitution
Contributor Cindy H. Dubin highlights innovations from key players in parenteral delivery and prefilled syringes, with focuses on safety, meeting regulatory requirements, cost, fill/finish, and dosing.
SCALING MANUFACTURING - Collaboration Between a Device Supplier & Equipment Manufacturer to Meet the Needs of Patients, End-Users & Pharma Manufacturers
John Merhige and William (“Bill”) Jaworski present how their two companies have worked closely together, using creative manufacturing strategies to produce a wide array of problem-solving drug delivery systems.
EXECUTIVE INTERVIEW - Adare Pharma Solutions: Expanding Capabilities to Exceed Customer Expectations
Tom Sellig, CEO of Adare Pharma Solutions, discusses how he has realized various achievements and about the company’s focus on addressing special needs in the market, its global expansion, and where he expects to take the company in the future.
DRUG & DEVICE DEVELOPMENT - Integration of siRNA, Nanoparticles & Capsule Endoscopy for Treatment of Inflammatory Bowel Disease
Nila Murali, Leia Jiang, and Ravali Bhavaraju highlight a promising technology that can change the way IBD is treated. Current imaging technology can successfully identify inflammation, and current treatments can address active inflammation and manage symptoms.
CELL & GENE THERAPY - It’s Time to Build Infrastructure to Handle the Coming Surge
Fran Gregory says the complexities and innovations associated with the production of cell and gene therapies also necessitates a shift in infrastructure, which will affect manufacturers, distributors, and providers. From development, manufacturing, storage, and delivery to patients; each step in the process requires forging a new path.
FORMULATION FORUM - Prefilled Syringes: Overcoming the Challenges for Safe & Accurate Delivery of Drugs
Shaukat Ali, PhD, and Jim Huang, PhD, provide a better understanding about some of the advantages of prefilled syringes, methods for manufacturing, and the syringe types commercially available.
MannKind to Proceed With Phase 1 Nintedanib DPI Study for Pulmonary Fibrotic Diseases
MannKind Corporation recently announced it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic pulmonary fibrosis…
Biora Therapeutics Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600
Biora Therapeutics, Inc. recently announced completion of dosing for the multiple-ascending dose cohorts for its clinical study of BT-600, a drug-device combination consisting of the…
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals With Alpha-1 Antitrypsin Deficiency
Wave Life Sciences Ltd. recently announced the approval of its first clinical trial application (CTA) for its RestorAATion-2 clinical trial of WVE-006, the company’s first-in-class…
Biotts Becomes First Company to Successfully Deliver Insulin Through Skin
Patients with Type 1 diabetes could replace up to 20 insulin injections over a period of five days….
FORMULATION DEVELOPMENT - The Rising Need for an Integrated Approach to Small Molecules Drug Development
Julian Northen, PhD, believes as the demands of a changing society evolve and continue to act as a driver for the identification of novel small molecules, the roles and diversity of the available medicines will also change.
EXECUTIVE INTERVIEW - Cocrystal Pharma: Utilizing Structure-Based Technologies to Provide First- & Best-In-Class Antiviral Drugs to Address Critically Unmet Medical Needs
Dr. Sam Lee, Cocrystal Pharma’s President and co-CEO, discusses the company’s latest achievements in antiviral drug development.
DRY POWDER FORMULATION - Preparing to Deliver the Next Generation of Inhaled Therapeutics
Richard Johnson, PhD, outlines the trends and challenges within the inhaled drug delivery market. Specifically, DPI delivery will be explored, including how the challenges with dry powder formulation can be overcome and what the future holds for DPIs.
